Andreas K. Buck

Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes

BACKGROUND: Patient selection for rechallenge peptide receptor radionuclide therapy (re-PRRT) in neuroendocrine tumors (NET) remains poorly defined. As re-PRRT is increasingly considered in clinical practice, identifying patients most likely to benefit has become a critical yet u...